The Potential for a Brighter, More Independent Future

Why It Matters

A Promising Path in Autism

Learn More

New Hope for Families

Understand the Impact

There are currently no approved pharmacologic treatments for Autism Spectrum Disorder (ASD) that target its cause and symptoms. PaxMedica is on a promising path to change that, bringing hope to millions.

PaxMedica is a clinical-stage biopharmaceutical company focused on developing innovative treatments for unmet needs in neurodevelopmental disorders.

Our lead programs are focused on Autism Spectrum Disorder (ASD).

About Autism Spectrum Disorder (ASD)

Autism Spectrum Disorders are characterized by extreme versions of the processes that govern the ability to (1) focus attention, and (2) filter out sensory input. While these often bring with them a wide range of special abilities — including the ability to hyperfocus on specific tasks — they also can make normal everyday interactions and activities more challenging, not only for people with autism, but also for those around them, beginning with their families.

PaxMedica’s lead product in development may help eliminate, reduce, or modulate some of the more troublesome aspects of these processes. That opens the potential for people with autism to integrate their behavior with others more successfully and improve their lives. And that would be a significant advance for them and everyone they touch — families, friends, and the larger world around them.

Behavioral Signs of Autism¹

Sensory Behaviors

Relating Behaviors

Body and Object Use Behaviors

Language Behaviors

Social and Self-help Behaviors

Did you know?

1 in 44 children in the US is born with autism²

It manifests between 18 months and 3 years of age³

It affects 4 times more boys than girls⁴

In the United States...

of autistic children are not admitted to regular schools⁵

of children with autism are bullied⁶

of autistic children are misdiagnosed⁷

more children are diagnosed every year⁸

Despite the enormous burden on children and families, there are currently no FDA-approved treatments for the core symptoms of ASD.

PaxMedica is on a promising path to change that, bringing hope to millions.

Our Pipeline

We are building a robust pipeline of products targeting Autism Spectrum Disorder and related neurodevelopmental conditions.

Learn More

Other areas of focus

We have committed to developing innovative treatments for some of the world’s most challenging neurodevelopmental conditions.

FXTAS

Fragile X-Associated Tremor/Ataxia

HAT

Human African Trypanosomiasis

Latest News

All news

January 7, 2022

PaxMedica Plans to Initiate Phase 1B Study for PAX-101 in Patients with Long COVID-19 Syndrome

Study has been approved by the South African Health Authority for individuals with documented COVID-19 infections who develop debilitating physical and neuropsychiatric symptoms that persist for...

July 19, 2021

PaxMedica selected by American Academy of Child and Adolescent Psychiatry (AACAP) to Present Data from its Recent Phase 2 Trial of PAX-101 (IV suramin) in Children with Autism Spectrum Disorder (ASD) in the Research Pipeline Program

David Hough, MD, CMO of PaxMedica will present trial results at the upcoming AACAP Annual Meeting during the “Research Pipeline: New Findings on Diagnostics and Therapeutics” program...

February 9, 2021

PaxMedica Announces Positive Results from Phase 2 Trial of PAX-101 (IV suramin) in Children with Autism Spectrum Disorder (ASD)

PAX-101 demonstrated sustained improvements over placebo in the trial’s primary and several secondary endpoints and a favorable safety and tolerability profile

1. Behavior Checklist for identifying severely handicapped individuals with high levels of autistic behavior

2. Autism Statistics and Facts

3. The Emergence of Autism Symptoms Prior to 18 Months of Age: A Systematic Literature Review

4. Autism Statistics and Facts

5. Quality of high school programs for students with autism spectrum disorder

6. The Case of Individuals with Autism Spectrum Disorder

7. Autism Misdiagnosis: How Common Is It?

8. Latest CDC autism figures show 15 percent rise